tezacaftor
Jump to navigation
Jump to search
Indications
- cystic fibrosis in combination with ivacaftor[1][2]
Dosage
Mechanism of action
- CFTR potentiator (presumably)
More general terms
Component of
References
- ↑ 1.0 1.1 1.2 Taylor-Cousar JL, Munck A, McKone EF et al Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med 2017; 377:2013-2023. Nov 23, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29099344 Free full text <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1709846
- ↑ 2.0 2.1 Rowe SM, Daines C, Ringshausen FC et al Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017; 377:2024-2035. Nov 23, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29099333 Free full text <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1709847